NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

352.50 3.50 (1.00%)

2.7M NSE+BSE Volume

NSE 09 Oct, 2025 3:31 PM (IST)

47,128

Market Cap

Market Leader

1.2

Beta 1Year

Very High Volatility

US FDA Approval

Biocon's arm gets US FDA nod for its ANDA for Rifaximin tablets, with a $1.8 billion market size See details

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Search Inside the pdf :

Biocon Ltd.

03 Oct 2025

352.50

1.00%

BIOCON LTD

Sell: Biocon Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Biocon Ltd is a biopharmaceutical company that develops therapies for chronic diseases such as autoimmune, cancer and diabetes. The company has developed and introduced novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogues. In Q1FY26, Biocon's consolidated revenue grew 14.8% YoY to Rs. 3,942cr, driven...

Promoters have decreased holdings from 60.64% to 54.45% in Jun 2025 qtr

Biocon Ltd.

11 Aug 2025

352.50

1.00%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock with a target price of Rs 380/share, implying an 11% upside potential from the CMP.

Mutual Funds have increased holdings from 8.77% to 15.24% in Jun 2025 qtr.

Biocon Ltd.

09 Aug 2025, 12:00AM

352.50

1.00%

Margin pressure persists

Sell: Biocon Ltd.

Target

ICICI Securities Limited

Biocon’s Q1FY26 performance was marred by operating cost of new facilities for generic division and lower-thananticipated margins in biologics division.

Promoters have decreased holdings from 60.64% to 54.45% in Jun 2025 qtr

Biocon Ltd.

08 Aug 2025

352.50

1.00%

Temporary headwinds in generics weigh on 1Q

Buy: Biocon Ltd.

Target

Motilal Oswal

Biocon (BIOS) reported lower-than-expected financial performance in 1QFY26, affected mainly by a sharp reduction in generics sales and increased opex related to new facilities.

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

03 May 2025

352.50

1.00%

Pick of the Week:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We recommend BUY with TP of Rs 351, which implies an upside of 10% from the current market price (CMP).

Promoters have decreased holdings from 60.64% to 54.45% in Jun 2025 qtr

Biocon Ltd.

01 Feb 2025

352.50

1.00%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock with a target price of Rs 405/share, implying a 12% upside potential from CMP

Geojit BNP Paribas downgraded Biocon Ltd. to Sell with a price target of 312.0 on 03 Oct, 2025.

Biocon Ltd.

13 Jan 2025

352.50

1.00%

‘VAI’ status for Malaysian site provides regulatory boost

Buy: Biocon Ltd.

Recommendation Target

Motilal Oswal

Biocon (BIOS) has received ‘Voluntary Action Indicated’ (VAI) status for its Malaysian site. With this, BIOS now has all critical sites for biosimilars under USFDA compliance, improving its business prospects in the US market.

Number of FII/FPI investors increased from 305 to 333 in Jun 2025 qtr.

Biocon Ltd.

20 Nov 2024

352.50

1.00%

BIOCON LTD

Accumulate: Biocon Ltd.

Target

Geojit BNP Paribas

Number of FII/FPI investors increased from 305 to 333 in Jun 2025 qtr.

Biocon Ltd.

12 Nov 2024

352.50

1.00%

Soft quarter, expect recovery in H2

Buy: Biocon Ltd.

Sharekhan

Revenues stood at Rs. 3,590 crore, up 4% y-o-y and a 5% rise q-o-q. EBITDA reached Rs. 730 crore, down 1% y-o-y but up 24% q-o-q. PAT stood at Rs. 27 crore, a decline of 84% y-o-y and 97% q-o-q.